Advertisement
Loading...

Transcenta Holding Limited

6628.HKHKSE
Healthcare
Biotechnology
HK$1.60
HK$0.02(1.27%)
Hong Kong Market is Open • 11:26
Advertisement

Transcenta Holding Limited Fundamental Analysis

Transcenta Holding Limited (6628.HK) shows weak financial fundamentals with a PE ratio of -2.99, profit margin of -31.04%, and ROE of -28.13%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.10

Areas of Concern

ROE-28.13%
Operating Margin-30.67%
Cash Position2.17%
Current Ratio0.25
We analyze 6628.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -2921.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-2921.5/100

We analyze 6628.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

6628.HK struggles to generate sufficient returns from assets.

ROA > 10%
-20.34%

Valuation Score

Excellent

6628.HK trades at attractive valuation levels.

PE < 25
-2.99
PEG Ratio < 2
-0.10

Growth Score

Weak

6628.HK faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

6628.HK shows balanced financial health with some risks.

Debt/Equity < 1
0.20
Current Ratio > 1
0.25

Profitability Score

Weak

6628.HK struggles to sustain strong margins.

ROE > 15%
-2813.32%
Net Margin ≥ 15%
-31.04%
Positive Free Cash Flow
No

Key Financial Metrics

Is 6628.HK Expensive or Cheap?

P/E Ratio

6628.HK trades at -2.99 times earnings. This suggests potential undervaluation.

-2.99

PEG Ratio

When adjusting for growth, 6628.HK's PEG of -0.10 indicates potential undervaluation.

-0.10

Price to Book

The market values Transcenta Holding Limited at 0.91 times its book value. This may indicate undervaluation.

0.91

EV/EBITDA

Enterprise value stands at -3.13 times EBITDA. This is generally considered low.

-3.13

How Well Does 6628.HK Make Money?

Net Profit Margin

For every $100 in sales, Transcenta Holding Limited keeps $-31.04 as profit after all expenses.

-31.04%

Operating Margin

Core operations generate -30.67 in profit for every $100 in revenue, before interest and taxes.

-30.67%

ROE

Management delivers $-28.13 in profit for every $100 of shareholder equity.

-28.13%

ROA

Transcenta Holding Limited generates $-20.34 in profit for every $100 in assets, demonstrating efficient asset deployment.

-20.34%

Following the Money - Real Cash Generation

Operating Cash Flow

Transcenta Holding Limited generates limited operating cash flow of $-128.70M, signaling weaker underlying cash strength.

$-128.70M

Free Cash Flow

Transcenta Holding Limited generates weak or negative free cash flow of $-133.62M, restricting financial flexibility.

$-133.62M

FCF Per Share

Each share generates $-0.31 in free cash annually.

$-0.31

FCF Yield

6628.HK converts -21.69% of its market value into free cash.

-21.69%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.99

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.10

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.91

vs 25 benchmark

P/S Ratio

Price to sales ratio

97.12

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.20

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.25

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.28

vs 25 benchmark

ROA

Return on assets percentage

-0.20

vs 25 benchmark

ROCE

Return on capital employed

-0.26

vs 25 benchmark

How 6628.HK Stacks Against Its Sector Peers

Metric6628.HK ValueSector AveragePerformance
P/E Ratio-2.9928.32 Better (Cheaper)
ROE-28.13%733.00% Weak
Net Margin-3103.72%-53055.00% (disorted) Weak
Debt/Equity0.200.38 Strong (Low Leverage)
Current Ratio0.254.03 Weak Liquidity
ROA-20.34%-19488.00% (disorted) Weak

6628.HK outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Transcenta Holding Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ